Literature DB >> 12942392

American cutaneous leishmaniasis, lepromatous leprosy, and pulmonary tuberculosis coinfection with downregulation of the T-helper 1 cell response.

Pierre Delobel1, Pascal Launois, Felix Djossou, Dominique Sainte-Marie, Roger Pradinaud.   

Abstract

Cutaneous leishmaniasis, leprosy, and tuberculosis are caused by intracellular pathogens whose development depends on impaired cell-mediated immunity. We report an exceptional triple association of American cutaneous leishmaniasis, lepromatous leprosy, and pulmonary tuberculosis in a man with no recognized immunodeficiency. Normal immunological assessment of the interferon-gamma pathway does not support the hypothesis of a genetic defect in any of the genes involved in the T helper (Th)-1 cytokine cascade in this patient. Unresponsiveness to interleukin (IL)-12 of his T cells after stimulation with Leishmania guyanensis, Mycobacterium bovis bacille Calmette-Guérin, and Mycobacterium leprae antigens suggested the inability to mount an appropriate Th cell response to upregulate the IL-12 receptor expression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12942392     DOI: 10.1086/376632

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  12 in total

Review 1.  Vaccines: all things considered.

Authors:  Ken S Rosenthal; Daniel H Zimmerman
Journal:  Clin Vaccine Immunol       Date:  2006-08

Review 2.  Leprosy and tuberculosis co-infection: clinical and immunological report of two cases and review of the literature.

Authors:  Maria Ângela B Trindade; Denise Miyamoto; Gil Benard; Neusa Y Sakai-Valente; Dewton de M Vasconcelos; Bernard Naafs
Journal:  Am J Trop Med Hyg       Date:  2012-12-03       Impact factor: 2.345

3.  Coexistence of cutaneous tuberculosis (scrofuloderma) and hanseniasis-a rare presentation.

Authors:  Chandan Kumar Das; Ashoka Mahapatra; Manasi Manaswini Das; Debasish Sahoo; Nirupama Chayani
Journal:  J Clin Diagn Res       Date:  2014-02-03

4.  Coinfection of two age old diseases.

Authors:  Mary Grace
Journal:  Indian J Community Med       Date:  2011-07

5.  Lepromatous leprosy and perianal tuberculosis: a case report and literature review.

Authors:  Maria Rita Parise-Fortes; Joel Carlos Lastória; Silvio Alencar Marques; Maria Stella Ayres Putinatti; Hamilton Ometto Stolf; Mariângela Ester Alencar Marques; Vidal Haddad
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2014-08-27

Review 6.  Tegumentary leishmaniasis and coinfections other than HIV.

Authors:  Dalila Y Martínez; Kristien Verdonck; Paul M Kaye; Vanessa Adaui; Katja Polman; Alejandro Llanos-Cuentas; Jean-Claude Dujardin; Marleen Boelaert
Journal:  PLoS Negl Trop Dis       Date:  2018-03-01

7.  A Case-Control Study on the Association Between Intestinal Helminth Infections and Treatment Failure in Patients With Cutaneous Leishmaniasis.

Authors:  Dalila Y Martínez; Alejandro Llanos-Cuentas; Jean-Claude Dujardin; Katja Polman; Vanessa Adaui; Marleen Boelaert; Kristien Verdonck
Journal:  Open Forum Infect Dis       Date:  2020-05-12       Impact factor: 3.835

Review 8.  Co-infection of tuberculosis and parasitic diseases in humans: a systematic review.

Authors:  Xin-Xu Li; Xiao-Nong Zhou
Journal:  Parasit Vectors       Date:  2013-03-22       Impact factor: 3.876

9.  Interleukin-10-dependent down-regulation of interferon-gamma response to Leishmania by Mycobacterium leprae antigens during the clinical course of a coinfection.

Authors:  R B G Azeredo-Coutinho; D C S Matos; J A C Nery; C M Valete-Rosalino; S C F Mendonça
Journal:  Braz J Med Biol Res       Date:  2012-05-10       Impact factor: 2.590

10.  Polymerase chain reaction detection of Leishmania DNA in skin biopsy samples in Sri Lanka where the causative agent of cutaneous leishmaniasis is Leishmania donovani.

Authors:  Shalindra Ranasinghe; Renu Wickremasinghe; Sanjeeva Hulangamuwa; Ganga Sirimanna; Nandimithra Opathella; Rhaiza D C Maingon; Vishvanath Chandrasekharan
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-12-11       Impact factor: 2.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.